Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHF10136
- Development stage
- Phase 1
- Lead developer
- Chiesi
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
CHF10136 is an investigational inhaled drug candidate being developed by Chiesi Farmaceutici for the treatment of asthma. Administered via a dry powder inhaler (DPI), the therapeutic is designed to target airway inflammation and bronchoconstriction associated with asthma. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy subjects and patients with mild to moderate-to-severe asthma.
Beyond the preview
Go deeper on CHF10136.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHF10136.